...times and high costs - because current lab tests and disease models (in vitro) don’t adequately predict drug effect in the patient (in vivo). To address this “Challenge”, three leading EU SMEs; Luxcel Biosciences Ltd, Axiogenesis AG and BMG Labtech GmbH, are partnering to bring to market, a fully integrated targeted metabolomics Test Platform, comprising physiologically relevant in vitro cell assa ...